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A B S T R A C T
In this review we describe the expanding repertoire of molecular tools with which to study gene function in
Leishmania. Speciﬁcally we review the tools available for studying functions of essential genes, such as plasmid
shuﬄe and DiCre, as well as the rapidly expanding portfolio of available CRISPR/Cas9 approaches for large scale
gene knockout and endogenous tagging. We include detail on approaches that allow the direct manipulation of
RNA using RNAi and protein levels via Tet or DiCre induced overexpression and destabilization domain medi-
ated degradation. The utilisation of current methods and the development of more advanced molecular tools will
lead to greater understanding of the role of essential genes in the parasite and thereby more robust drug target
validation, thereby paving the way for the development of novel therapeutics to treat this important disease.
1. Introduction
Genetics is a powerful tool for understanding the molecular me-
chanisms that regulate Leishmania life cycle progression and host-
parasite interactions [1]. Despite some notable exceptions [2], forward
genetic approaches have proved challenging in Leishmania due to su-
pernumerary chromosomes [3,4] and the complexities of carrying out
sexual crosses within the sandﬂy [5], which has hindered positional
cloning as a method for characterising genes generating speciﬁc phe-
notypes. In contrast, the availability of Leishmania genome sequences
[6,7], readily searchable using the online resource TritrypDB [8] and a
decent toolkit for reverse genetic manipulation of the parasite [1,9] has
enabled the study of non-essential genes encoding proteins that facil-
itate infection and identiﬁed essential genes that regulate fundamental
cellular processes. For the most part these studies have focussed on loss
of function analysis using genetic manipulation of individual genes by
exploiting the inherent propensity of Leishmania to undergo homo-
logous recombination to insert transgenes into the genome. Gene re-
placement is performed by transfection of procyclic promastigotes with
a linear vector containing a drug resistance cassette ﬂanked by arms of
homology for the target gene locus [10]. For single copy genes on
disomic chromosomes two rounds of transfection with independent
drug selectable markers are generally required to generate a null mu-
tant [10], although loss of heterozygosity can result in a null mutant in
one round of transfection [11]. Gene deletion mutants can then be
evaluated for their ability to replicate in culture as procyclic promas-
tigotes, diﬀerentiate to metacyclic promastigotes and axenic amasti-
gotes or infect macrophages, animals or sandﬂies. Direct transfection of
axenic amastigotes is a feasible but rarely performed method [12].
Despite the eﬃcacy of Leishmania gene replacement with transgenes
containing ﬂanks homologous to the endogenous gene locus, the ap-
proach is limited to proof of principle when replacing genes that are
essential to promastigote viability. In such instances the genomic
plasticity of Leishmania can result in the selection of aneuploidy, or cells
with extrachromosomal elements that retain a copy of the target gene
despite replacement [13,14]. The selection of such cells provides sup-
porting evidence of an important role for the gene, but is not suﬃcient
to prove essentiality or to study the function of essential genes. Ex-
pression of an ectopic copy of the target gene from an episome, or via
integration into the genome, enables replacement of endogenous gene
copies without the selection of clones with altered ploidy, retention of
this episome in the absence of selection can provide evidence that a
gene is required for proliferation. Episomal complementation can also
be used as an elegant means to probe essentiality in vivo as recovery of
parasites retaining the episome after murine infection evidences the
selective pressure exerted on amastigotes to express the essential gene
from the plasmid [15,16]. A number of vectors are available for over-
expression that either integrate into the ribosomal locus and provide
constitutive expression of a gene of interest [17,18], or function as
episomes [19]. Overexpression of a gene can also give key insights as to
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the biological role of an essential gene when dominant negative phe-
notypes arise. Overexpression may also be applied to mode of action
studies, for example where increased protein levels render cells sus-
ceptible to a drug by increased activation of a prodrug to a cytotoxic
metabolite, such as the bio-activation of bicyclic-nitro drugs by the L.
donovani nitroreductase NTR2 [20]. Equally, overexpression can enable
the assessment of drug resistance mechanisms, and has recently been
employed to elucidate targets conferring resistance to a variety of anti-
leishmanial compounds following expression of Leishmania genes from
cosmids [21].
In recent years methods for reverse genetic modiﬁcation of
Leishmania for elucidating gene function have expanded, primarily due
to the adaption of existing systems previously utilised in model or-
ganisms such as yeast for regulating essential gene, transcript and
protein expression. This review will evaluate these new methods and
speculate how future advances will enhance our ability to investigate
these organisms further.
2. New tools for assessing if Leishmania genes are essential for
cellular proliferation
Since the establishment of transfection and homologous re-
combination to conduct gene replacement in Leishmania, proteins have
been identiﬁed which are essential to the survival of the parasites.
Essentiality can manifest itself in a variety of ways; a lethal phenotype
in all life-cycle stages [22,23], a conditional lethal phenotype where
cell survival is dependent on growth conditions such as nutrient
availability [24], or essentiality in one life cycle stage but not another
[2426]. The inability to generate a null mutant can imply essentiality
and has been interpreted as the encoded protein being a genetically
validated drug target, however by adhering to these criteria a gene can
only be provisionally identiﬁed as a drug target. Functional analysis of
proteins encoded by essential genes through conditional regulation of
gene expression is therefore highly desirable in Leishmania to facilitate
the phenotypic validation of proteins as drug targets, particularly if
utilised in a disease context such as murine infection or infection of
human macrophage. Until recently the prospect for performing such
studies in Leishmania were severely limited; fortunately the molecular
toolkit for regulating gene, transcript and protein expression in Leish-
mania has expanded in recent years. This is particularly important for
the genetic drug target validation.
2.1. Plasmid shuﬄe
A more reﬁned approach to test if a gene is essential has been
adapted from ﬁssion yeast for use in Leishmania. This plasmid shuﬄe
methodology expands on episomal complementation to confer negative
selection against expression of the transgene; expression in tandem with
a thymidine kinase (TK) suicide cassette confers sensitivity to gancli-
covir (GCV) [27] (Fig. 1A). Active TK synthesises GCV into the toxic
metabolite GCV triphosphate which inhibits DNA synthesis, thereby
exerting strong selective pressure for the loss of the plasmid. The in-
clusion of positive marker cassettes for drug resistance and green
ﬂuorescent protein (GFP) facilitate clonal selection and downstream
gene expression analysis. By this method, a negative selection line can
be generated by episomal complementation and subsequent en-
dogenous gene replacement. Both the L. major DHCH gene encoding a
dual-function protein involved in 10-Formyl-THF metabolism [27] and
the L. donovoni CYP51 genes have been identiﬁed as essential to pro-
mastigote survival by their retention on a TK expression plasmid in the
presence of GCV treatment [28].
A further development of this technique enables the generation of
partial essential gene null mutants for functional analysis of protein
domains by complementation by loss of the TK plasmid and subsequent
retention of a second, TK absent plasmid encoding a mutated copy of
the gene [29,30] (Fig. 1A). The application of plasmid shuﬄe for the
identiﬁcation of residues essential for protein function represents an
important advance. In the ﬁrst of these studies [29] phosphoproteomic
analysis identiﬁed a complex implicated in the regulation of the heat-
shock response elicited when promastigotes are inoculated into the
mammalian host. An amastigote speciﬁc chaperone complex STI1/HOP
was identiﬁed and subsequently manipulated by endogenous STI1 de-
letion in the presence of an episomal copy in array with the TK and GFP
cassettes. After negative selection with GCV the plasmid was retained
and the encoded protein established as essential. Further com-
plementation of the plasmid shuﬄe line was conducted with a re-
pertoire of secondary episomes containing diﬀerent STI1 genes that had
been mutated at potential phosphorylation sites. Negative selection
following complementation with ﬁve such mutated sequences enabled
the identiﬁcation of two phosphoserine residues essential for the
function of the encoded chaperone. Plasmid shuﬄe was also applied to
show that L. major map kinase 4 (MPK4), a protein kinase which is
implicated in mediating diﬀerentiation through the life cycle, is es-
sential [30]. By further complementation of this line with MPK4 ATP
binding site mutants, partial null mutants were assessed by GCV treat-
ment to establish clones which replicated in the presence of negative
selection, but had altered protein kinase activity in subsequent diﬀer-
entiation assays. Inducible complementation allowed the identiﬁcation
of the K59R residue MPK4 expressing mutants which underwent in-
creased metacyclic diﬀerentiation in vitro but had reduced intracellular
macrophage survival [30].
The rapid adoption of plasmid shuﬄe is testament to the novel
biological insights that can be uncovered for a target gene. Its appli-
cation to a variety of genes in diﬀerent contexts represents the ﬂex-
ibility of plasmid shuﬄe to probe gene function.
2.2. DiCre recombinase
Genome engineering by Cre recombinase mediated excision of se-
quences ﬂanked by locus of crossover of bacteriohage P1 (loxP) sites
has been utilised in mammalian systems for over twenty years, but until
recently had not been applied to Leishmania, possibly because of the
lack of a tightly regulated system for induction. One method for reg-
ulating Cre expression utilizes a split Cre enzyme fused as two inactive
fragments with a FK506-binding protein (FKBP12) and the binding
domain of the FKBP12-rapamycin associated protein (FRB) [31].
Treatment with rapamycin dimerises the Cre (DiCre) subunits to re-
constitute recombinase activity, and the expression of Cre as non-
functional subunits is an elegant method to alleviate any side-eﬀects of
overexpression of active, potentially cytotoxic Cre.
This approach was applied to the study of the L. mexicana cdc-2
related protein kinase 3 (CRK3), which had previously been suggested
to be essential using gene replacement approaches [22], The strategy
involved replacing the ﬁrst CRK3 allele with the DiCre sequence and the
second with a loxP ﬂanked (ﬂoxed) copy of the gene (CRK3 Flox),
thereby generating a cell line in which gene deletion could be induced
upon activation of DiCre by treatment with rapamycin (Fig. 1B) [23].
By conditional gene deletion CRK3 activity was identiﬁed as essential
for the transition of procyclic promastigotes through G2/M leading to
growth arrest, aberrant cells and cell death. A conditional com-
plementation approach was also employed whereby the generation of a
cell line expressing a T-loop residue CRK3T178E mutant refractory to
DiCre mediated excision failed to recover normal cellular function,
demonstrating the essentiality of this residue in regulating CRK3 ac-
tivity. A beneﬁt of this approach when compared with mutant trans-
gene complementation by plasmid shuﬄe is that the resulting mutant
expressing predominantly the mutated transgene in the absence of the
ﬂoxed copy to enable the resulting phenotype to be directly assessed. In
addition the DiCre complementation approach necessitates one less
round of transfection compared with the four rounds necessary for
plasmid shuﬄe.
Attempts to ablate genes in the amastigote life cycle stage resulted
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in gene loss but were hindered by the increased sensitivity of this life
cycle stage to rapamycin treatment, potentially as a result of rapamycin
inhibiting the activity of Leishmania target of rapamycin (TOR) proteins
[32]. The use of alternative dosage strategies and rapamycin analogues
with reduced binding to Leishmania TORs may circumvent such con-
straints and as a consequence of the existing limitations with regulating
amastigote gene expression the analysis of conditionally null amasti-
gotes is a highly desirable tool to probe the function of essential genes
in the mammalian life cycle stage. To circumvent the inherent sensi-
tivity of amastigotes to rapamycin, CRK3 loss was induced for 24 h in
bioluminescent, stationary phase promastigotes and assessed for their
proliferation in mice. CRK3 deﬁcient parasites were signiﬁcantly re-
duced in their ability to proliferate in vivo, indicating the importance of
CRK3 for establishing infection.
The future application of DiCre to murine and macrophage infec-
tions will be important for the identiﬁcation of Leishmania drug targets
and alternatives to the rapamycin inducible DiCre system exist, where
recombinase activity can be induced by diﬀerent conditions, such as
photo-inducible Cre [33] or a homo-dimerisable Cre that is activated by
ligands with more beneﬁcial pharmacokinetic properties and reduced
binding to endogenous FKBP [34]. Such alternatives could facilitate
conditional gene deletion during murine infection or in vitro macro-
phage infection. Further optimisation of the Cre recombinase metho-
dology holds great promise for investigating Leishmania essential genes
in more biologically relevant contexts.
2.3. CRISPR/Cas9
The CRISPR/Cas9 DNA genome editing methodology has been ap-
plied successfully to Leishmania and is set to revolutionize the way the
parasite is genetically manipulated [3537]. Cas9 is an RNA dependent
DNA endonuclease and the system requires the expression of the Cas9
enzyme concurrently with a single guide RNA composed of a sequence
complementary to the target site (marked by a conserved PAM se-
quence), fused to a scaﬀold RNA (Fig. 2A). In Leishmania, CRISPR-Cas9
induced double stranded breaks can be repaired by homologous re-
combination if a DNA template is provided, or by micro-homology
mediated end joining (MMEJ). Non-homologous end joining (NHEJ) is
thought to be absent in Leishmania [38,39]. The application of this
technology in Leishmania has enhanced gene deletion and endogenous
tagging capability [3537] (http://www.leishgedit.net/Home.html).
Several diﬀerent approaches have been taken for Cas9 editing in
Leishmania promastigotes. Sollelis and co-workers [36] generated a
Cas9 expression plasmid that was stably maintained in L. major al-
lowing subsequent transfection with a linearized sgRNA expression
cassette that also contained a large homology-ﬂanked drug resistance
marker to completely delete the gene of interest (the PFR2 gene array)
(Fig. 2B). The sgRNA was transcribed under the control of the PolIII U6
Fig. 1. The current molecular toolkit for analysis of essential Leishmania genes A. Plasmid shuﬄe utilises episomal expression of a target gene open reading frame (ORF) with the negative
selectable thymidine kinase (TK) and positive markers for green ﬂuorescent protein (GFP) and drug resistance (DrugR) [30]. Transgene complementation enables deletion of endogenous
gene copies and ganciclovir (GCV) treatment induces selection for plasmid retention and the expression of GFP if essential or loss of expression if non-essential. A fourth round of
complementation with a mutated version of the target gene ORF enables the identiﬁcation of active residues within the encoded protein. By GCV negative selection, retention of the ORF
and GFP expression is indicative of a deleterious mutation which prevents active protein expression. In contrast, loss of the non-mutated ORF by inducible complementation the mutant
gene identiﬁes a functional mutated protein. B. Dimerizable Cre recombinase (DiCre) enables the generation of conditional null mutants [23]; the ﬁrst allele of the ORF is replaced by a
targeting construct comprising the two inactive Cre subunits (Cre59 and Cre60) each fused to FKBP12 (FK506-binding protein) and FRB (binding domain of the FKBP12-rapamycin
associated protein) together with a drug resistance marker. The second allele is replaced with a loxP ﬂanked (ﬂoxed) ORF copy expressed together with a second drug resistance cassette.
Treatment with rapamycin causes the subunits to form an active Cre recombinase leading to excision of the ﬂoxed ORF to enable downstream phenotyping of null mutants. Com-
plementation can be carried out with wild type of mutant transgenes.
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promoter and both the Cas9 expression plasmid and modiﬁcation were
selected for using separate antibiotics. Oﬀ-target eﬀects of CRISPR/
Cas9 in Leishmania should be low, due to the small genome size and the
selection of appropriate guide sequences with online resources such as
EuPaGDT [40] and indeed that appears to be the case [36]. Zhang and
Matlashewski [35] conducted their study in L. donovani, and used re-
sistance to miltefosine as a readout of editing eﬃciency. Cas9 and
sgRNAs were encoded on separate plasmids but the authors varied the
mode of gene editing (Fig. 2C). Initially this study targeted the LdMT
gene and relied on the MMEJ pathway to create point mutations and
deletions in the LdMT gene. This disruption was also conducted by co-
transfecting with a ssDNA oligonucleotide containing homology to the
LdMT gene ﬂanking an array of stop codons to disrupt the gene. In-
sertion of a short homology ﬂanked, drug resistance cassette was also
demonstrated into two further genes (both essential and non-essential).
The ability to tag endogenous genes was also demonstrated by fusing
the LdMT gene with a homology ﬂanked GFP. Insertional disruption in
LdMT conferred functional resistance to miltefosine but complete de-
letion was only achieved using a dual guide system that created double
stranded breaks at the 5 and 3 ﬂanks of LdMT thus deleting the entire
locus. Unusually in this study, the sgRNAs were expressed under the
control of the rRNA promoter and used a ribozyme sequence to ter-
minate sgRNA transcription, making it diﬀerent from most other
CRISPR/Cas9 systems. The same group reﬁned their system further to
include all the elements required for CRISPR/Cas9 editing on a single
plasmid, in theory making this applicable to diﬀerent Leishmania spe-
cies [37]. This study also demonstrated the ability of the system to
disrupt multicopy tandem gene arrays, as well as separate loci on
diﬀerent chromosomes to induce chromosome translocations; the
ability to edit loci without including selectable markers was also used
by generating point mutations in the RAD51 gene. In an informative
experiment diﬀerent promoters for guide RNA generation were assessed
for eﬃciency, demonstrating that the PolI driven rRNA promoter is
more eﬃcient than the PolIII driven U6 promoter, allowing for optimal
design of future systems.
Another recent and promising use of CRISPR/Cas9 technology in
Leishmania sp. is exempliﬁed by the work done in the laboratory of Eva
Gluenz [41]. L. mexicana and L. major cell lines expressing T7 RNA
polymerase and Cas9 were transfected with PCR generated DNA cas-
settes that expressed sgRNAs and PCR generated repair cassettes, sim-
plifying the process of generating mutants (Fig. 2D). This was high-
lighted by the transfection of parasites with sgRNA cassettes and two
diﬀerent repair cassettes to edit two alleles of the PF16 gene simulta-
neously in an endogenous tagging experiment, and to delete both copies
of the PF16 and LPG1 genes in separate experiments, leading to func-
tional defects in non-clonal populations. Presented as a resource this
study also contains a library of template plasmids to allow generation of
gene deletion and tagging cassettes; a primer design tool is included at
an accompanying website (http://www.leishgedit.net/Home.html).
The technique is not inducible, so only non-essential genes can be fully
deleted in a manner that gives meaningful information on the pheno-
type of the null mutant. However, the ﬂexibility, rapidity and eﬃciency
of this system means it is likely to become a method of choice for the
initial characterization of gene families in Leishmania.
The utilization of CRISPR/Cas9 in Leishmania is still in the early
stage of development; therefore it will be beneﬁcial to employ a variety
Fig. 2. CRISPR/Cas9 in Leishmania. A. Expression of Cas9 and single guide RNAs (sgRNAs) in Leishmania promastigotes, allows the sgRNA to guide Cas9 to the speciﬁed target location,
adjacent to a protospaceradjacent motif (PAM, in this instance NGG or NAG). Cas9 then induces a double strand break (DSB), which can be repaired by several mechanisms such as
microhomology mediated end joining (MMEJ) or homologous recombination (HR). A variety of systems have been developed to achieve this result. B. The approach by Sollelis et al. [36]
used an L. major cell line that constitutively expressed Cas9 from an episome, the sgRNA was expressed from a linear cassette under control of the L. major U6 promoter. The long
homology arms of the drug resistance cassette were 1 kb in size and were contained in the same construct as the sgRNA, which was linearized with ScaI prior to transfection. C. Zhang
et al. [35] generated a strain of L. donovani that also expressed Cas9 from a stable episome, and used a second episome to express the sgRNAs. This episome used the rRNA promoter to
initiate transcription of the sgRNA and the hepatitis delta virus (HDV) ribozyme to terminate transcription, guides could be multiplexed using the Hammerhead ribozyme (HH) to process
arrayed guide cassettes. A variety of repair templates could be used to disrupt genes of interest, including MMEJ, and short-homology ﬂanked oligos or PCR products. This system was
later developed into a single plasmid method [37]. D Beneke et al. [41] generated strains of L. mexicana and L. major that expressed Cas9 and T7 RNA polymerase (T7RNAP) from the
tubulin locus, sgRNAs and repair cassettes were provided as linear PCR products. sgRNAs were expressed under the control of a T7 RNAP promoter and repair cassettes were ﬂanked with
30 bp homology regions, multiplexing of guides and repair cassettes was conducted by combining PCR products and achieving high transfection eﬃciencies using the Amaxa 2b
Nucleofector system.
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of strategies to establish the optimal approach for genome editing of
this organism. For studies that aim to understand parasite virulence in
vivo eﬃcient techniques are required to rapidly edit genetic loci in
species and strains that lose virulence after prolonged culture or ex-
tensive modiﬁcation in vitro, mitigating the diﬃculties that slower,
traditional techniques might present. A beneﬁcial property of CRISPR/
Cas9 is the ability to ablate multiple alleles of a gene in one round of
selection; this has important implications for the study of Leishmania as
many potentially important genes are encoded on supernumerary
chromosomes [3] rendering their manipulation diﬃcult by current gene
replacement methods. The study of gene dosage, a phenomenon in
which Leishmania alter gene expression by copy number variation is
implicated in drug resistance [42], virulence and the rapid adaptation
of promastigotes and amastigotes to survival in culture media or in vivo
is an exciting area of Leishmania biology which would beneﬁt greatly
from CRISPR/Cas9 mediated manipulation. A current limitation is the
lack of an inducible CRISPR/Cas9 that could be used to delete essential
genes. Such limitations could be circumvented by the conditional ac-
tivation of CRISPR/Cas9, for example using a split-Cas9 [43] or tetra-
cycline inducible expression. Further development and optimization of
the technology is going to be needed to facilitate genome-wide studies
on Leishmania to identify cohorts of essential genes that encode pro-
mising drug targets.
3. New tools for regulating gene expression
The ability to regulate the level of gene expression enables in-depth
studies into the function of the expressed protein. The ability to reduce
or up-regulate gene expression to alter protein concentration is im-
portant for drug target validation, target deconvolution and identifying
mechanisms of resistance; increased protein expression confers drug
resistance if they speciﬁcally target the activity of the up-regulated
protein by sequestering the compound, whilst reducing gene expression
will result in increased susceptibility as protein levels are reduced. The
ability to regulate gene expression in a conditional manner is chieﬂy
important when low levels of expression are insuﬃcient to perform
their biological function, or if levels rise above a threshold that causes
dominant-negative eﬀects that impair cell viability. In such instances
the results of altered expression can be very informative, particularly
when expressing mutated genes to infer functions of individual amino
acids, such as active site residues, within a protein. In addition, in-
creasingly high-throughput and practical methods for endogenous gene
tagging enable the localisation of their products and enable expression
levels to be quantiﬁed. The repertoire for conducting such work has
expanded in recent years, thereby advancing our ability to assess gene
function by altering expression levels.
3.1. RNAi
RNA interference (RNAi) is an established and tractable tool for
down regulation of gene expression. The RNAi pathway functions by
the expression of Dicer-like enzymes DCL1 and 2 which process long
double stranded (ds) RNA into small, double stranded duplexes. dsRNA
is sliced into single stranded siRNA and loaded as a guide sequence by
Argonaute enzyme mediated processing, forming the RNA-inducing
silencing complex (RISC) to degrade full length transcript [44]
(Fig. 3A). RNAi as a method for functional analysis of genes in parasite
species such as L. major and L. donovani is non-functional due to the
evolutionary loss of Dicer-like and Argonaute proteins [45]. In contrast,
the retention of such cellular machinery in the L. (Viannia) enables
RNAi as a method for functional analysis of genes in parasite species
such as L. braziliensis. Functional RNAi was established in this species by
electroporation of promastigotes with dsRNA, yielding variability in the
eﬃcacy of this method by low levels of knockdown against mediators of
LPG expression (LPG1, LPG2, LPG3) but eﬃcient reduction of paraﬂa-
gellar rod protein (PFR1 and PFR2) expression.
The highly variable levels of RNAi knockdown elicited for non-es-
sential transcript is challenging, whilst the absence of an inducible
method for dsRNA generation limits the approach to non-essential
targets. Yet the approach is useful to reduce the expression of proteins
which are encoded as multi-copy genes whereby gene replacement is
unfeasible. A recent study by utilised RNAi in L. braziliensis to knock
down expression of amastin which is encoded by 52 genes across 9
diﬀerent chromosomes [46]. The method for RNAi in L. braziliensis
relies on the transfection of dsRNA or a stem-loop construct to initiate
gene silencing, however as both approaches lack temporal regulation of
the generation of dsRNA and render the method unfeasible for essential
genes.
New technologies may emerge that can inducibly deplete mRNA
levels, for example components of CRISPR/Cas systems can include
enzymes with alternative substrate speciﬁcity, such as C2c2, which can
degrade RNA [47]. Development of an inducible C2c2 system would
ideally allow for speciﬁc depletion of a chosen mRNA, although ap-
plying this system in a meaningful manner is currently hindered by
signiﬁcant oﬀ target mRNA degradation.
3.2. Tetracycline inducible gene expression
Induction of gene expression by tetracycline treatment has been a
highly desirable tool in Leishmania due to the widespread utilisation of
this approach in other trypanosomatids. This system requires the ex-
pression of T7 RNA polymerase and tetracycline repressor (TetR) pro-
teins in conjunction with an expression cassette containing a T7 pro-
moter sequence downstream of a TetR binding operon (TetO) and a site
for cloning in a gene of interest. Attempts to regulate gene expression in
L. donovani were previously hindered by high background activity and
variable levels of expression depending on the RNA polymerase med-
iating gene expression [48]. Promisingly, the recent development of a
transgenic Leishmania mexicana cell line expressing the TetR and T7
polymerases from the ribosomal locus has enabled the development of a
system for conditional gene expression [49] (Fig. 3B). The reverse or-
ientation of this cassette reduces background expression, and the au-
thors demonstrate no detectable expression of a reporter gene in the
absence of tetracycline by immunoblotting. This system has the po-
tential to be used to generate conditional null mutants, where cells
contain a tetracycline inducible ectopic copy of a gene of interest and
both allelic copies are replaced by drug resistance genes, as described in
Trypanosoma brucei [50]. Removal of tetracycline exerts TetR function
to ablate gene expression and allow a null phenotype to be assessed.
The ability to regulate Leishmania gene expression by tetracycline
treatment is highly desirable during murine or hamster infection.
Studies into genes required for infection of the mammalian host are
possible as the orally bioavailable, tetracycline analogue doxycycline is
widely used. Such studies would require suﬃcient expression of the
exogenous TetR and T7 Pol genes in intracellular amastigotes, but a
recent study into the expression of T7 Pol revealed dramatically re-
duced levels of protein expression in both metacyclic promastigotes and
amastigotes [51], so optimisation is required.
3.3. DiCre recombinase inducible gene expression
The ﬂexibility of loxP recombination, in addition to the tight reg-
ulation of DiCre activity, opens up the possibility of achieving inducible
gene expression mediated by DiCre recombinase. Inducible expression
requires an antisense gene of interest to be ﬂanked with cis rather than
trans orientated loxP sites. Upon Cre activation, loxP recombination
induces the inversion of the antisense sequence to enable RNA poly-
merase mediated transcription (Fig. 3C), whilst the use of left and right
element (LE/RE) mutated lox sites prevents continual recombination
and inversion. This ﬂip methodology has recently been validated in L.
major procyclic promastigotes by conditional expression of the DNA
damage response protein Rad9 by diCre recombinase-mediated gene
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inversion [52]. This methodology opens up the possibility of per-
forming conditional mutant overexpression to induce dominant nega-
tive phenotypes in promastigotes, but it has the same limitations for
amastigotes as described above for diCRE mediated gene deletion.
4. New tools for endogenous protein tagging and regulating
protein levels
The ability to regulate protein levels is complementary to genetic
based approaches because of diﬀering kinetics of protein loss or gain.
This can result in the rapid manifestation of phenotypes dependent on
protein half-life opposed to slower onset phenotypes that are buﬀered
by existing cellular mRNA and protein content following inducible gene
deletion. However, a constraint of protein manipulation is the
requirement for tagging of the protein; this can be problematic if tag-
ging prevents protein function. As such, studies directly manipulating
protein stability in Leishmania are less common compared with genetic
techniques, yet manipulation of protein levels can be a very powerful
and robust method.
4.1. Endogenous tagging
Expression of epitope tagged proteins in Leishmania has typically
been carried from episomal plasmids, which is eﬀective but can give
variable levels of expression of the fusion protein in individual cells
[19]. An alternative is C- or N- terminal tagging of endogenous genes,
which requires long homology arms for successful integration, but
which has been simpliﬁed with a fusion PCR approach [53] (Fig. 4A).
Fig. 3. Regulation of gene transcription. A. Functional RNAi pathway in Leishmania. L. braziliensis enables targeting of mRNA by integration of an RNAi targeting sequence into a
ribosomal small subunit (SSU) integrative construct [45]. Transfection of the stem-loop construct generates dsRNA by transcription from the ribosomal RNA (rRNA) promotor. Dicer-like
(DCL) enzymes process the dsRNA into siRNA duplexes that are processed into single stranded siRNA by Argonaute (AGO1) and loaded to form the RNA-induced silencing complex
(RISC). B. Tetracycline overexpression system [49]. The T7 RNA polymerase and Tet Repressor elements are integrated into the rRNA locus. A gene under control of the tet operator is
expressed from the tubulin locus in the opposite direction to normal transcription to prevent leaky expression (denoted by the opposing arrowheads on ORF, Tag and DrugR elements).
Tetracycline is added to release inhibition of the cassette by the tet repressor and T7 dependent transcription of the gene proceeds. C. DiCre ORF Flipping Overexpression [52]. An
episomal or integrated (not shown) construct can be prepared where the ORF is opposing the promoter and is ﬂoxed by the inverted, directional lox66 and lox77 sites. DiCre induction by
rapamycin induces ﬂipping of the ORF into the correct orientation for transcription but cannot be ﬂipped back due to the formation of lox72 and loxP sites, leading to inducible expression
of the GOI.
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This approach does not involve cloning therefore it is rapid and scal-
able. Unfortunately Leishmania genes cannot be tagged using cassettes
ﬂanked by short homology (80100 bp) contained in oligonucleotide
primers used to make the cassettes [53]. This long primer approach is
the basis for the tagging of almost the entire proteome in the TrypTag
project [54], and would be welcome in the Leishmania ﬁeld as it is
simpler, cheaper and more rapid than the fusion PCR method. Despite
short-homology ﬂanked cassettes not integrating eﬃciently into wild-
type Leishmania, the application of CRISPR/Cas9 has revolutionised the
ﬁeld, allowing for 30 bp ﬂanked cassettes to eﬃciently integrate close
to a Cas9-induced, double stranded break [41] (Fig. 4B). The ﬂexibility
of this system has been increased by the development of a series of
vectors allowing genes to be tagged with elements encoding proteins of
diﬀerent function; these include BirA* for proximity dependent bioti-
nylation, NanoLuc and HaloTag for probing protein:protein interactions
by BRET assay, and various epitope and ﬂuorescent markers such as
mNeonGreen. These can be applied to both N- and C-terminal tagging.
By combining the rapid process of the T7/Cas9 system with new, highly
advanced protein tags such as mNeonGreen and BirA* the possibility of
proteome-wide localisation and interactome projects has now become
technically feasible in Leishmania.
4.2. Conditional protein destabilisation
An approach to regulate protein expression by conferring inducible
stability involves the linkage of a target protein to a regulatory, de-
stabilisation domain (dd) derived and modiﬁed from an FKBP domain.
The ddFKBP domain leads to proteasome-mediated degradation when
the stabilising ligand is absent. Protein stability and therefore activity is
conferred by treatment with the synthetic ligand Shld-1 (Fig. 4C) and
was utilised eﬀectively in L. major promastigotes to stabilise UDP-
galactopyranose mutase (ddUGM), an enzyme involved in the bio-
synthesis of lipophosphoglycan (LPG) [55]. By integration of a ddGLF
construct into a homozygous, glf− null mutant L. major line, stability of
a dd conjugated UDP-galactopyranose mutase (ddUGM) was con-
ferrable by Shld-1 treatment, with removal of Shld-1 rapidly resulting
in the inducible susceptibility to complement mediated lysis due to
expression of LPG truncated in the glycan region [55]. The system has
also been used to study the dynamics of Leishmania ﬂagellum proteins
during diﬀerentiation [56].
The utilisation of dd to study the function of Leishmania proteins
held great promise, however it was not until recently that the system
was used to regulate the stability of an essential protein [57]. Previous
work using individual UDP-sugar pyrophosphorylase (USP) and UDP-
Glc pyrophosphorylase (UGP) null mutants implicated their encoded
proteins in sugar salvage and the biosynthesis UDP-sugars [58,59].
Individual UGP and USP null mutants were viable, but double null
mutants could not be generated thereby implicating the requirement for
at least one enzyme for suﬃcient sugar nucleotide synthesis for ade-
quate protein glycosylation and parasite viability. To further elucidate
the role of USP a cell line was generated expressing a single copy of the
UDP-sugar pyrophosphorylase (USP) conjugated to the destabilisation
domain in a cell line deﬁcient in the enzyme UDP-Glc pyropho-
sphorylase (UGP). ddUSP expression in the presence of the stabilising
ligand FK506 was suﬃcient to maintain the pools of sugar nucleotides
UDP-Glc and UDP-Gal but in the absence of ligand the resulting loss of
ddUSP led to the depletion of these sugars and cell death. This elegant
study demonstrates the potential for dd-tagging of essential proteins in
Leishmania and the ability to combine destabilisation domain tagging
with CRISPR/Cas9 approaches may allow more rapid generation of
mutants where both alleles are dd-tagged in a single transfection, in-
creasing the potential throughput.
Fig. 4. Protein tagging and manipulation. A. Epitope tagging can be eﬀectively performed by transfecting a 500 bp homology ﬂanked cassette containing a tag in frame with the gene of
interest. These cassettes are eﬃciently constructed by a 3-fragment fusion PCR, and can be used in unmodiﬁed Leishmania strains. Panel A depicts N-terminal tagging but this strategy can
be applied to C-terminal or internal contexts [53]. B. CRISPR/Cas9 mediated epitope tagging is more rapid and eﬃcient as the epitope tag can be generated by PCR with short homology
PCR but necessitates a strain expressing functional CRISPR/Cas9 system [41]. C. Destabilization domain tagging of proteins. An allele of a gene can be tagged with a destabilization
domain using the approaches in panel A or B, and the remaining WT allele removed by replacement with a drug selectable marker (or double knockout in the presence of an episomal
complementation vector). Protein of interest fused to the dd tag is stabilized by the addition of the Shield-1 or trimethoprim ligand, removal of the ligand triggers protein destabilization,
and consequent degradation, allowing downstream phenotyping.
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Another inducible protein destabilisation system based on the
Escherichia coli dihydrofolate reductase destabilizing domain (ecDHFR)
that uses a diﬀerent ligand, trimethoprim, has recently been reported in
Leishmania [60]. This ligand is cheaper than Shld-1 and provides an
alternative to the ddFKBP system.
5. Concluding remarks
Reviewed here is the rapidly expanding repertoire of molecular
tools with which to study essential regulators of Leishmania. It is hoped
that the utilisation of current methods and the development of ever
more advanced molecular tools will enhance the identiﬁcation and
validation of genes encoding essential, druggable targets thereby
paving the way for the development of novel therapeutics to treat this
neglected disease.
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